Country: Israel
Language: English
Source: Ministry of Health
TRIPTORELIN ACETATE
FERRING PHARMACEUTICALS LTD
L02AE04
SOLUTION FOR INJECTION
TRIPTORELIN ACETATE 0.1 MG/ML
S.C
Required
FERRING GmbH ,GERMANY
TRIPTORELIN
Precocius puberty, prostatic cancer, endomethriosis, uterus myomatoses and IVF.
2017-10-29
1 1. NAME OF THE MEDICINAL PRODUCT. DECAPEPTYL ® 0.1 MG 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 disposable syringe with 1 ml solution for injection contains 100 ug triptorelin acetate, corresponding to 95.6 ug triptorelin. For excipients see 6.1. 3. PHARMACEUTICAL FORM. Solution for injection 4. CLINICAL PARTICULARS. 4.1 THERAPEUTIC INDICATIONS Precocious puberty, prostatic cancer, endometriosis, uterus myomatoses, IVF. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _PROSTATIC CANCER _ _Dosage. _ Initially, Decapeptyl 0.5 mg is administered once a day for 7 days. From the 8th day on, Decapeptyl 0.1 mg is administered once a day. Alternativelly, Decapeptyl Depot (3.75 mg triptorelin as controleed-release preparation for IM application once every 28 days) is available. _Mehtod and duration of administration. _ Decapeptyl 0.1 mg and 0.5 mg are injected subcutaneously. Decapeptyl is foreseen for long-term treatment. The duration of therapy is fixed by the physician in charge. Decapeptyl 0.5 mg is foressen for the initial phase of treatment over 7 days; long-term treatment is carried out by Decapeptyl Depot and/or Decapeptyl 0.1 mg. A switch from other forms of application of GnRH-analogues is possible without problems any time. 4.3 CONTRAINDICATIONS - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 - Hypersensitivity to gonadotrophin-releasing hormone (GnRH) or any other GnRH analogue - Pregnancy and Lactation period Non hormone dependent carcinoma. Prostatic cancer: Decapeptyl should not be prescribed to patients presenting with spinal cord compression or evidence of spinal cord metastases. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE The use of GnRH agonists may cause reduction in bone mineral density. In men, preliminary data suggest that the use of a bisphosphonate in combination with an GnRH agonist may reduce bone mineral loss. Particular caution is necessary in patients with additional risk factors for osteoporosis (e.g. chronic alcohol abuse, smokers, long-term the Read the complete document